CA2981301A1 - Compositions and methods of treatment of breast disorders and estrogen-related disorders - Google Patents

Compositions and methods of treatment of breast disorders and estrogen-related disorders Download PDF

Info

Publication number
CA2981301A1
CA2981301A1 CA2981301A CA2981301A CA2981301A1 CA 2981301 A1 CA2981301 A1 CA 2981301A1 CA 2981301 A CA2981301 A CA 2981301A CA 2981301 A CA2981301 A CA 2981301A CA 2981301 A1 CA2981301 A1 CA 2981301A1
Authority
CA
Canada
Prior art keywords
breast
fatty acid
composition
vitamin
omega
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2981301A
Other languages
English (en)
French (fr)
Inventor
Steven C. Quay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atossa Therapeutics Inc
Original Assignee
Atossa Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atossa Genetics Inc filed Critical Atossa Genetics Inc
Publication of CA2981301A1 publication Critical patent/CA2981301A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2981301A 2015-04-14 2016-04-06 Compositions and methods of treatment of breast disorders and estrogen-related disorders Abandoned CA2981301A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562147536P 2015-04-14 2015-04-14
US62/147,536 2015-04-14
PCT/US2016/026170 WO2016168021A1 (en) 2015-04-14 2016-04-06 Compositions and methods of treatment of breast disorders and estrogen-related disorders

Publications (1)

Publication Number Publication Date
CA2981301A1 true CA2981301A1 (en) 2016-10-20

Family

ID=57127000

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2981301A Abandoned CA2981301A1 (en) 2015-04-14 2016-04-06 Compositions and methods of treatment of breast disorders and estrogen-related disorders

Country Status (7)

Country Link
US (1) US20180049999A1 (cg-RX-API-DMAC7.html)
EP (1) EP3283061A4 (cg-RX-API-DMAC7.html)
JP (1) JP2018514511A (cg-RX-API-DMAC7.html)
CN (1) CN107708678A (cg-RX-API-DMAC7.html)
AU (1) AU2016247674A1 (cg-RX-API-DMAC7.html)
CA (1) CA2981301A1 (cg-RX-API-DMAC7.html)
WO (1) WO2016168021A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180169034A1 (en) * 2015-06-14 2018-06-21 Trs Ii, Llc Transdermal delivery formulation
CA2992282A1 (en) * 2015-07-14 2017-01-19 Atossa Genetics Inc. Transpapillary methods and compositions for treating breast disorders
CN110099680B (zh) 2016-10-11 2021-02-05 杜克大学 Er+乳腺癌的拉索昔芬治疗
CN111212635A (zh) * 2017-09-11 2020-05-29 阿托莎医疗公司 局部用组合物
EP3681491A4 (en) 2017-09-11 2021-06-30 Atossa Therapeutics, Inc. PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES
TW201919594A (zh) * 2017-09-11 2019-06-01 美商艾陶莎基因有限公司 局部用組合物及治療方法
CA3094072A1 (en) * 2018-03-15 2019-09-19 Atossa Therapeutics, Inc. In situ methods of inducing of immune response
CN117771239A (zh) 2018-04-10 2024-03-29 杜克大学 乳腺癌的拉索昔芬治疗
WO2019232485A1 (en) * 2018-05-31 2019-12-05 Nvigen, Inc. Accurate blood test to predict cancer incidence, recurrence, guide and monitor treatment intervention
US12390435B2 (en) 2018-11-14 2025-08-19 University of Pittsburgh—of the Commonwealth System of Higher Education Electrophiles and electrophile pro-drugs as RAD51 inhibitors
IT201900003843A1 (it) * 2019-03-15 2020-09-15 Lo Li Pharma Srl Trattamento di fibromi con vitamina D e un agente come l'epigallocatechina gallato (EGCG)
EP3980006A2 (en) * 2019-06-07 2022-04-13 Diomics Corporation Topical time release delivery using layered biopolymer
WO2021003433A1 (en) * 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
BR112022001165A2 (pt) * 2019-07-23 2022-05-17 Scherer Technologies Llc R P Formulações de cápsula de casca macia e métodos de preparação e uso das mesmas
US11915811B2 (en) * 2019-09-03 2024-02-27 Kaival Labs, Inc. System and method for determining an appropriate dose of a product
KR20220154196A (ko) * 2020-03-18 2022-11-21 알.피.쉐러 테크놀러지즈 엘엘씨 연질겔 캡슐
WO2021231904A1 (en) * 2020-05-14 2021-11-18 Diomics Corporation Detection and indication of covid-19, other viruses and pathogens and vaccine associated efficacy
CN111420046B (zh) * 2020-05-27 2021-01-12 四川省畜牧科学研究院 一种动物疫苗佐剂及其制备方法
WO2022187511A1 (en) * 2021-03-03 2022-09-09 Veramorph Llc Dissociating polymer matrix compositions of fulvestrant and methods of their making and use
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
KR102864596B1 (ko) * 2022-04-25 2025-09-26 유엠에스엔지니어링 주식회사 오메가 3 심리스 연질캡슐 제조방법
WO2025174794A1 (en) * 2024-02-12 2025-08-21 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149851A (en) * 1990-10-25 1992-09-22 The United States Of America As Represented By The Secretary Of Commerce Process for preparing triglycerides containing polyunsaturated fatty acid moieties
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
DE19738643C2 (de) * 1997-09-04 2001-10-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Scopolaminbase und Verfahren zu seiner Herstellung
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
DE20013336U1 (de) * 2000-08-02 2001-02-15 Bieger, Wilfried P., Priv.-Doz. Dr.med.habil., 80335 München Mund- und Zahnpflegegel
NZ552316A (en) * 2006-12-22 2009-10-30 Fonterra Co Operative Group Dairy product and process
WO2008113177A1 (en) * 2007-03-20 2008-09-25 Centre De Recherche Sur Les Biotechnologies Marines Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
US20090068190A1 (en) * 2007-08-29 2009-03-12 Drugtech Corporation Anti-proliferative combinations
WO2014093313A1 (en) * 2012-12-10 2014-06-19 Jingxuan Kang Compositions and methods for integrated metabolic interventions
US8728546B1 (en) * 2013-03-15 2014-05-20 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer, cardiovascular diseases and inflammation
MX370055B (es) * 2013-04-22 2019-11-29 Smartfish As Uso de una composición que comprende aceite de pescado y jugo para el tratamiento y/o postratamiento de cáncer.
CN103734512A (zh) * 2013-12-20 2014-04-23 晓健科技(大连)有限公司 一种宠物猫补钙营养膏
CA2992282A1 (en) * 2015-07-14 2017-01-19 Atossa Genetics Inc. Transpapillary methods and compositions for treating breast disorders

Also Published As

Publication number Publication date
EP3283061A4 (en) 2019-04-17
EP3283061A1 (en) 2018-02-21
JP2018514511A (ja) 2018-06-07
WO2016168021A1 (en) 2016-10-20
AU2016247674A1 (en) 2017-10-19
CN107708678A (zh) 2018-02-16
US20180049999A1 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
US20180049999A1 (en) Compositions and methods of treatment of breast disorders and estrogen-related disorders
RU2737496C2 (ru) Способы лечения рака
EP3630078B1 (en) Chemoembolization agents
CN115698013B (zh) Menin抑制剂和cyp3a4抑制剂的组合及其使用方法
TW201927304A (zh) 尼拉帕尼(niraparib)調配物
CN111132670A (zh) 具有增强的渗透的药物组合物
WO2010138652A1 (en) Methods for treating kaposi sarcoma
CN102413821A (zh) 经皮吸收型制剂
JP7784400B2 (ja) ホットフラッシュの新規処置法
CN102065900B (zh) 经皮吸收促进剂和使用其的经皮给药制剂
JP2025087753A (ja) メトピマジンの新規多形形態
TW201919608A (zh) 局部用組合物
KR20060127875A (ko) 아로마타제 억제제 요법-관련된 골다공증의 치료
TW201919594A (zh) 局部用組合物及治療方法
TW200901989A (en) Anti-tumor activity of CCI-779 in papillary renal cell cancer
Lee et al. In vitro delivery of anti-breast cancer agents directly via the mammary papilla (nipple)
TW201325584A (zh) 治療皮膚腫瘤的方法
KR102258514B1 (ko) 신규한 다층형 좌약 제제
TW202532086A (zh) 治療對卡介苗療法無反應之高風險非肌肉侵襲性膀胱癌之方法
EP4479043A1 (en) Oxphos inhibitors for use in treating cancer
JP2009286759A (ja) デンプンを素材とする徐放性支持体、および徐放性固形製剤への応用
HK40060074A (en) Liposomal enhanced intra-peritoneal chemotherapy
HK40027656B (en) Chemoembolization agents
WO2016135262A1 (en) No donors for the treatment of impaired tissue perfusion

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220301